Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (221-230 of 347) with videos related to

Pageof 35
Sort By:
Chinese Journal of Cancer|September 16, 2015
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphomaYuankai Shi, Ping Zhou, Xiaohong Han, et al.
Annals of Hematology|October 20, 2023
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort studyQiaofeng Zhong, Haizhu Chen, Daoguang Chen, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 29, 2021
Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphomaYuankai Shi, Qingyuan Zhang, Xiaohong Han, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2024
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapyShasha Wang, Xuezhi Hao, Liyuan Dai, et al.
Eclinicalmedicine|July 15, 2024
Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trialYuankai Shi, Keshu Zhou, Hui Zhou, et al.
Cancer Research and Treatment|October 14, 2021
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung CancerYu Feng, Yutao Liu, Mingming Yuan, et al.
Journal of Translational Medicine|October 11, 2019
Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapyXiaohong Han, Ying Han, Qiaoyun Tan, et al.
Zhonghua Yi Xue Za Zhi|April 29, 2016
[Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma]Yu Huang, Shengyu Zhou, Xiaohui He, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2024
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsQiaoyun Tan, Ruyun Gao, Xiaomei Zhang, et al.
Carcinogenesis|March 5, 2013
Risk of genome-wide association study-identified genetic variants for non-Hodgkin lymphoma in a Chinese populationYan Qiao, Yuling Zhou, Chen Wu, et al.
Pageof 35

Showing results (221-230 of 347) with videos related to

Sort By:
Pageof 35
Chinese Journal of Cancer|September 16, 2015
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphomaYuankai Shi, Ping Zhou, Xiaohong Han, et al.
Annals of Hematology|October 20, 2023
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort studyQiaofeng Zhong, Haizhu Chen, Daoguang Chen, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 29, 2021
Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphomaYuankai Shi, Qingyuan Zhang, Xiaohong Han, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2024
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapyShasha Wang, Xuezhi Hao, Liyuan Dai, et al.
Eclinicalmedicine|July 15, 2024
Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trialYuankai Shi, Keshu Zhou, Hui Zhou, et al.
Cancer Research and Treatment|October 14, 2021
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung CancerYu Feng, Yutao Liu, Mingming Yuan, et al.
Journal of Translational Medicine|October 11, 2019
Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapyXiaohong Han, Ying Han, Qiaoyun Tan, et al.
Zhonghua Yi Xue Za Zhi|April 29, 2016
[Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma]Yu Huang, Shengyu Zhou, Xiaohui He, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2024
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsQiaoyun Tan, Ruyun Gao, Xiaomei Zhang, et al.
Carcinogenesis|March 5, 2013
Risk of genome-wide association study-identified genetic variants for non-Hodgkin lymphoma in a Chinese populationYan Qiao, Yuling Zhou, Chen Wu, et al.
Pageof 35